Vaxinano featured prominently this week with the disclosure of a new peer-reviewed study in MDPI Animals detailing a trivalent inactivated in ovo nanovaccine targeting avian colibacillosis in broilers. The company describes it as the first reported inactivated in ovo vaccine for this indication, highlighting strong immunogenicity, compatibility with live viral vaccines, and scalability on its nanovaccine platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The in ovo approach is designed to deliver protection before hatch, which could improve early and uniform flock immunity while reducing handling and labor in commercial hatcheries. These operational advantages may appeal to large poultry producers focused on efficiency, and the compatibility with existing live viral vaccines suggests potential fit with current hatchery vaccination practices.
Vaxinano is positioning the technology as a tool to support antimicrobial stewardship by reducing reliance on antibiotics through preventive vaccination. This aligns with global policy and industry trends aimed at curbing antimicrobial resistance in livestock, and could enhance the relevance of the company’s platform in regulatory and funding discussions.
The project benefits from support by the International Development Research Centre’s InnoVet AMR 1.0 program, signaling external interest and validation of its potential role in combating antimicrobial resistance. Such non-dilutive backing can help de-risk early-stage R&D and strengthen Vaxinano’s case in future fundraising, partnership, or co-development negotiations.
From an investor perspective, the publication reinforces Vaxinano’s scientific credibility and showcases a differentiated position in the high-volume poultry vaccine segment. While no timelines, regulatory milestones, or revenue projections were disclosed, successful progression from this scientific milestone to commercialization could expand the company’s addressable market and enhance its long-term standing in preventive animal health.
Overall, the week underscored steady progress in Vaxinano’s nanovaccine platform and its application to food-animal production, with growing external recognition but key commercial and regulatory steps still ahead.